A detailed history of Nebula Research & Development LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 12,738 shares of GILD stock, worth $1.49 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
12,738
Previous 30,129 57.72%
Holding current value
$1.49 Million
Previous $3.38 Billion 58.17%
% of portfolio
0.12%
Previous 0.31%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$96.91 - $113.0 $1.69 Million - $1.97 Million
-17,391 Reduced 57.72%
12,738 $1.41 Billion
Q1 2025

May 15, 2025

BUY
$89.14 - $117.41 $2.41 Million - $3.17 Million
27,009 Added 865.67%
30,129 $3.38 Billion
Q4 2024

Feb 14, 2025

BUY
$83.95 - $97.9 $261,924 - $305,448
3,120 New
3,120 $288 Million
Q1 2024

May 15, 2024

BUY
$71.58 - $87.29 $298,273 - $363,737
4,167 New
4,167 $305 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $146B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.